SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: SYS6010 is an antibody-drug conjugate targeting epidermal growth factor receptor (EGFR). We report the results of a phase 1 trial (ChiCTR2300072141) of SYS6010 in patients with non-small cell lung cancer (NSCLC). A total of 236 patients were treated. One dose-limiting toxicity occurred at 6.4 mg/kg; therefore, 4.2, 4.5, and 4.8 mg/kg were selected for cohort expansion. Treatment-related adverse events (TRAEs; any/grade ≥ 3) occurred in 99.6%/57.2% of patients. Common grade ≥3 TRAEs included neutropenia (30.9%), leukopenia (25.0%), and thrombocytopenia (17.4%). Objective response rate was 34.7% in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs) and platinum chemotherapy, 45.7% in EGFR-mutant NSCLC treated with EGFR TKIs, 20.0% in EGFR wild-type squamous NSCLC, and 35.7% in EGFR wild-type non-squamous NSCLC. Median progression-free survival and overall survival were 7.6 and 19.4 months, respectively, in EGFR-mutant NSCLC treated with EGFR TKIs and platinum chemotherapy. Overall, SYS6010 shows a manageable safety profile and encouraging antitumor activity in previously treated, advanced NSCLC.
Source: Cancer Cell
Authors: Zi-Ming Li, Zhen Zhou, Zhi-Yong He, Liang Han, Jian Fang, Hong-Mei Sun, Hai-Feng Liu, Ming-Xia Wang, Yi-Bing Liu, Xiu-Juan Qu, Yu Yao, Yi Gong, Yan Yu, Hua-Qiu Shi, Yan Wang, Chun-Xia Su, Kun-Yu Yang, Yan-Hong Shang, Jian Ruan, Xiang-Lin Yuan, Ming-Jun Zhang, Hui Luo, Jiu-Wei Cui, Xiao-Yan Lin, Meng-Xia Li, Hai-Zhou Lou, Run-Xiang Yang, Hao Wu, Xi-Cheng Wang, Mo Dan, Li-Qiong Zhang, Yang-Zhi Su, Xue-Chao Wan, Kai Zou, Ying-Ying Yang, Shun Lu
Institutions: Shanghai Jiao Tong University, Shanghai Chest Hospital, Fujian Provincial Cancer Hospital, Xuzhou Central Hospital, Peking University Cancer Hospital, Jilin Province Tumor Hospital, Fourth Hospital of Hebei Medical University, First Hospital of China Medical University, First Affiliated Hospital of Xi'an Jiaotong University, Chongqing University, Chongqing Cancer Hospital, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Gannan Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shanghai Pulmonary Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, Affiliated Hospital of Hebei University, First Affiliated Hospital Zhejiang University, Zhejiang University, Tongji Hospital, Second Affiliated Hospital of Anhui Medical University, Jiangxi Provincial Cancer Hospital, First Hospital of Jilin University, Union Hospital, Army Medical University, Sir Run Run Shaw Hospital, Jiangsu Province Hospital, Nanjing Medical University, First Affiliated Hospital of Guangdong Pharmaceutical University, CSPC Pharmaceutical Group
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $10,400
OpenAlex ID: W7202382305